The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash rent benefit | - | 76,773 |
| Net income (loss) | -139,748 | 1,948,863 |
| Depreciation | 674,312 | 1,334,646 |
| Amortization of intangible assets | 4,776 | 9,552 |
| Amortization and write-off of debt issuance costs and debt discounts | 51,191 | - |
| Stock-based compensation | 73,161 | 118,929 |
| Loss on disposal of property, plant and equipment | -62,319 | 2,263 |
| Non-cash rent benefit | 304,900 | - |
| Other assets | - | 20,251 |
| Trade accounts receivable | 175,943 | -1,392,310 |
| Inventory | 1,507,579 | 1,181,803 |
| Prepaid expenses and other current assets | 117,643 | 63,804 |
| Other assets | 10,977 | - |
| Amortization of debt issuance costs and debt discounts | - | 21,612 |
| Accounts payable and accrued expenses | 133,036 | -305,684 |
| Net cash provided by operating activities | -1,182,583 | 3,175,334 |
| Purchase of property, plant and equipment | 593,924 | 484,209 |
| Proceeds from sale of property, plant and equipment | 1,900 | 29,232 |
| Net cash used for investing activities | -592,024 | -454,977 |
| Proceeds from at-the-market offering, gross | 0 | 349,326 |
| Proceeds from debt issuance | 801,267 | - |
| Debt principal repayments | 1,124,323 | 761,544 |
| Payments of debt issuance costs and debt discounts | 14,633 | 0 |
| Payments of equity offering costs | 0 | 67,880 |
| Proceeds from exercise of stock options | 0 | 3 |
| Net cash (used for) provided by financing activities | -337,689 | -480,095 |
| Net increase in cash and cash equivalents | 127,966 | - |
| Cash and cash equivalents at beginning of period | 3,758,232 | - |
| Net increase in cash and cash equivalents | - | 2,240,262 |
| Cash and cash equivalents at end of period | 3,886,198 | - |
IMMUCELL CORP DE (ICCC)
IMMUCELL CORP DE (ICCC)